Compare QFIN & SYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | QFIN | SYRE |
|---|---|---|
| Founded | 2016 | 2013 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.6B |
| IPO Year | 2018 | 2016 |
| Metric | QFIN | SYRE |
|---|---|---|
| Price | $19.67 | $31.59 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | $36.85 | ★ $56.50 |
| AVG Volume (30 Days) | ★ 2.0M | 888.4K |
| Earning Date | 11-18-2025 | 11-04-2025 |
| Dividend Yield | ★ 7.80% | N/A |
| EPS Growth | ★ 40.93 | N/A |
| EPS | ★ 6.93 | N/A |
| Revenue | ★ $2,752,357,572.00 | N/A |
| Revenue This Year | $16.96 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $2.81 | ★ N/A |
| Revenue Growth | ★ 14.06 | N/A |
| 52 Week Low | $17.61 | $10.91 |
| 52 Week High | $48.94 | $35.31 |
| Indicator | QFIN | SYRE |
|---|---|---|
| Relative Strength Index (RSI) | 46.60 | 52.33 |
| Support Level | $18.80 | $32.50 |
| Resistance Level | $20.10 | $33.22 |
| Average True Range (ATR) | 0.70 | 1.40 |
| MACD | 0.23 | -0.56 |
| Stochastic Oscillator | 60.69 | 2.76 |
Qfin Holdings Inc Formerly Qifu Technology Inc is a Credit-Tech platform in China. It provides credit services more accessible and personalized to consumers and SMEs through Credit-Tech services to financial institutions, whereby it deploys its technology solutions to help financial institutions identify the diversified needs of consumers and SMEs, effectively access prospective borrowers that are creditworthy through multi-channels, enhance credit assessment on prospective borrowers, and manage credit risks and improve collection strategies and efficiency, among others.
Spyre Therapeutics Inc is a biotechnology company that aims to create the next-generation of inflammatory bowel disease (IBD) products by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. IBD is a chronic condition characterized by inflammation within the gastrointestinal tract, including two main disorders which are UC and CD. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.